• Consensus Rating: Buy
  • Consensus Price Target: C$4.67
  • Forecasted Upside:
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00
+0 (0.00%)

This chart shows the closing price for EVGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evogene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVGN

Analyst Price Target is C$4.67
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Evogene in the last 3 months. The average price target is C$4.67, with a high forecast of C$6.00 and a low forecast of C$4.00. The average price target represents a ∞ upside from the last price of C$0.00.

This chart shows the closing price for EVGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Evogene. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/24/2024Pi FinancialLower TargetC$5.00 ➝ C$4.00
12/12/2023DesjardinsLower TargetBuyC$4.25 ➝ C$4.00
11/24/2023DesjardinsLower TargetBuyC$4.50 ➝ C$4.25
11/24/2023Echelon Wealth PartnersLower TargetBuyC$6.25 ➝ C$6.00
9/25/2023DesjardinsLower TargetBuyC$4.50 ➝ C$4.25
8/25/2023DesjardinsBoost TargetBuyC$4.25 ➝ C$4.50
4/14/2023Pi FinancialLower TargetC$8.00 ➝ C$7.50
11/23/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformC$5.00 ➝ C$3.00
11/23/2022Pi FinancialLower TargetC$8.25 ➝ C$8.00
5/26/2022Royal Bank of CanadaLower TargetOutperformC$6.00 ➝ C$5.00
4/25/2022Royal Bank of CanadaLower TargetOutperformC$7.00 ➝ C$6.00
4/22/2022Echelon Wealth PartnersReiterated RatingBuyC$10.00
(Data available from 6/13/2019 forward)

News Sentiment Rating

-0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/16/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Evogene logo
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., seed traits through the Ag-Seeds division, and ag-solutions for castor oil production through Casterra Ltd.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Evogene?

The following Wall Street analysts have issued reports on Evogene in the last year: Desjardins, Echelon Wealth Partners, and Pi Financial.
View the latest analyst ratings for EVGN.

What is the current price target for Evogene?

3 Wall Street analysts have set twelve-month price targets for Evogene in the last year. Their average twelve-month price target is C$4.67. Echelon Wealth Partners has the highest price target set, predicting EVGN will reach C$6.00 in the next twelve months. Desjardins has the lowest price target set, forecasting a price of C$4.00 for Evogene in the next year.
View the latest price targets for EVGN.

What is the current consensus analyst rating for Evogene?

Evogene currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EVGN will outperform the market and that investors should add to their positions of Evogene.
View the latest ratings for EVGN.

What other companies compete with Evogene?

Other companies that are similar to Evogene include (EDW.V), (FSN.V), (FTE.V), 108946 (AUA.V) and 111040 (DNI.V). Learn More about companies similar to Evogene.